SHGClinical Trials•businesswire•
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Sentiment:Negative (30)
Summary
(NYSE:SHG) FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will share 17 scientific presentations from across its anti-infective programs at IDWeek 2025 (October 19-22, 2025) in Atlanta, Georgia. Presentations at IDWeek will feature new real-world evidence from three separate analyses from PROVE (Retrospective Cefiderocol Chart Review), the largest observational study to
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by businesswire